These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
91 related items for PubMed ID: 17953364
1. [Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models]. He YD, Peng ZL, Liu SL, Wang H, Pan XL. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):810-2. PubMed ID: 17953364 [Abstract] [Full Text] [Related]
2. [The rapid activation of human LAK cells and their inhibition on ovarian cancer at the advanced stage]. Song YF, Zhao YN, Li J. Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):332-5, 381. PubMed ID: 8001405 [Abstract] [Full Text] [Related]
3. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice]. Duan DS. Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993 Jun; 28(5):281-3, 314. PubMed ID: 8192930 [Abstract] [Full Text] [Related]
4. [Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells]. Kikuchi Y, Oomori K, Miyauchi M, Kita T, Kuki E, Iwano I, Hirata J, Nagata I. Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1891-5. PubMed ID: 2592812 [Abstract] [Full Text] [Related]
5. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2. Sacchi M, Snyderman CH, Heo DS, Johnson JT, d'Amico F, Herberman RB, Whiteside TL. Cancer Res; 1990 May 15; 50(10):3113-8. PubMed ID: 2334906 [Abstract] [Full Text] [Related]
6. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers. Nio Y, Zighelboim J, Berek JS, Bonavida B. Anticancer Res; 1990 May 15; 10(2A):441-6. PubMed ID: 2346317 [Abstract] [Full Text] [Related]
7. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy]. Wakizaka Y. Hokkaido Igaku Zasshi; 1992 Jul 15; 67(4):475-87. PubMed ID: 1330859 [Abstract] [Full Text] [Related]
8. [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo]. Chen QK, Yuan SZ. Zhonghua Zhong Liu Za Zhi; 1994 Sep 15; 16(5):353-5. PubMed ID: 7895586 [Abstract] [Full Text] [Related]
9. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells. Law KS, Chen HC, Liao SK. Anticancer Res; 2007 Sep 15; 27(2):841-50. PubMed ID: 17465210 [Abstract] [Full Text] [Related]
10. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I. Cancer Res; 1993 Jan 01; 53(1):94-100. PubMed ID: 8093231 [Abstract] [Full Text] [Related]
11. [Anti-human lung giant cell cancer (PG) effect of human LAK cells in vitro and in nude mice]. Deng HY. Zhonghua Zhong Liu Za Zhi; 1990 Jul 01; 12(4):258-60. PubMed ID: 2272258 [Abstract] [Full Text] [Related]
12. [Experimental expansion and antitumor effects of LAK cells from cancer patient's peripheral blood]. Zhang BX. Zhonghua Zhong Liu Za Zhi; 1992 Jul 01; 14(4):253-6. PubMed ID: 1396072 [Abstract] [Full Text] [Related]
13. [Effect of LAK cells and BRM on the growth of pancreatic cancer cells injected into nude mice]. Asano H, Kobari M, Yusa T, Kawakami K, Matsuno S. Nihon Geka Gakkai Zasshi; 1994 Sep 01; 95(9):678-88. PubMed ID: 7838109 [Abstract] [Full Text] [Related]
14. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Ayello J, van de Ven C, Fortino W, Wade-Harris C, Satwani P, Baxi L, Simpson LL, Sanger W, Pickering D, Kurtzberg J, Cairo MS. Biol Blood Marrow Transplant; 2006 Jun 01; 12(6):608-22. PubMed ID: 16737934 [Abstract] [Full Text] [Related]
15. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS. Exp Hematol; 2009 Oct 01; 37(10):1216-29. PubMed ID: 19638292 [Abstract] [Full Text] [Related]
16. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model. Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD. Surgery; 1990 Nov 01; 108(5):919-29. PubMed ID: 2237773 [Abstract] [Full Text] [Related]
17. [Antitumor effect of endothelial progenitor cells with TRAIL gene transfection on ovarian carcinoma xenografts in nude mice]. Zhou L, Yan MX, Yao M, Feng YJ. Ai Zheng; 2005 Nov 01; 24(11):1312-6. PubMed ID: 16552954 [Abstract] [Full Text] [Related]
18. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Senba T, Kuroki M, Arakawa F, Yamamoto T, Kuwahara M, Haruno M, Ikeda S, Matsuoka Y. Anticancer Res; 1998 Nov 01; 18(1A):17-24. PubMed ID: 9568050 [Abstract] [Full Text] [Related]
19. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P. In Vivo; 1999 Nov 01; 13(3):199-204. PubMed ID: 10459491 [Abstract] [Full Text] [Related]
20. [Lymphokine-activated killer cell induced from cord blood]. Wang YF, Jiang S. Zhonghua Fu Chan Ke Za Zhi; 1994 Feb 01; 29(2):78-81, 122-3. PubMed ID: 8033630 [Abstract] [Full Text] [Related] Page: [Next] [New Search]